Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Braxia Scientific Corp (OP: BRAXF )

0.0189 +0.0019 (+11.18%)
Streaming Delayed Price Updated: 3:53 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 176,197
Open 0.0190
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0170
Today's Range 0.0171 - 0.0200
52wk Range 0.0015 - 0.0852
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
Irwin Naturals Inc. 
Via Benzinga

Performance

YTD
+2.16%
+2.16%
1 Month
-59.79%
-59.79%
3 Month
-34.83%
-34.83%
6 Month
-59.53%
-59.53%
1 Year
-50.26%
-50.26%

More News

Read More
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Via Benzinga
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
Via Benzinga
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
Via Benzinga
6 Psychedelics Companies Take Action: Here Are The Latest, Major Announcements
Via Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Via Benzinga
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
Via Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Via Benzinga
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
Via Benzinga
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
Via Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
Via Benzinga
Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
Via Benzinga
Braxia Scientific Fiscal 2022 Revenue Grows 47.5% YoY, What About Net Loss?
Via Benzinga
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
Via Benzinga
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
Via Benzinga
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry
Via Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Via Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
Via Benzinga
New Study Suggests Ketamine Could Work Better Without Additional Antidepressants
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Via Benzinga
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Via Benzinga
Braxia Scientific Launches Broad Criteria Trial On Psilocybin For Depression
Via Benzinga
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.